Nkarta, Inc.
NKTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NKTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NKTX
Nkarta, Inc. is a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies for cancer, with a focus on advancing its pipeline through clinical trials while managing significant capital requirements and operating losses.
Key risk: Need for substantial additional funding
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 clinical trials for Nkarta, Inc..
Nkarta, Inc. is a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies for cancer, with a focus on advancing its pipeline through clinical trials while managing significant capital requirements and operating losses.
- Nkarta has an accumulated deficit of $648.3 million as of December 31, 2025 [sec_mda · as of 2026-03-25].
- The company raised $240.1 million in gross proceeds from a recent offering, before underwriting discounts and expenses [sec_mda · as of 2026-03-25].
- As of June 30, 2026, Nkarta reported cash and equivalents of $27.7 million and a net loss of $40.4 million for the period [sec].
- Nkarta expects to incur substantial expenses for clinical trials, manufacturing, and regulatory activities, requiring additional funding to support operations [sec_mda · as of 2026-08-10].
What works
- Nkarta successfully raised $240.1 million in gross proceeds, providing capital to advance its clinical programs [sec_mda · as of 2026-03-25].
- The company is focused on a novel NK cell therapy platform, which may offer differentiated treatment options in oncology [sec_mda · as of 2026-08-10].
What to weigh
- Nkarta has a significant accumulated deficit of $648.3 million and expects to continue incurring net losses, with no near-term revenue from product sales [sec_mda · as of 2026-03-25].
- The company will need substantial additional funding to support its operations and clinical trials, and may not be able to raise capital on acceptable terms [sec_mda · as of 2026-08-10].
- Clinical development is costly and uncertain, with the timing and results of trials posing risks to the company's progress [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
Nkarta has a large accumulated deficit and expects continued losses.
“As of December 31, 2025, we had an accumulated deficit of $648.3 million and anticipate that we will continue to incur net losses for the foreseeable future.”
SEC MD&A · March 25, 2026
Nkarta raised $240.1 million in gross proceeds from a recent offering.
“We raised $240.1 million in gross proceeds before underwriting discounts, commissions and other expenses of $15.0 million.”
SEC MD&A · March 25, 2026
Nkarta will need additional funding to support operations and clinical trials.
“We will need substantial additional funding to support our continuing operations and pursue our long-term development strategy, including the potential initiation of a pivotal stage clinical trial for any or all of our current development programs.”
SEC MD&A · August 10, 2026
Risks & what to watch (3)›
Key risks
- Need for substantial additional funding — Nkarta requires significant capital to continue operations and clinical trials, and may not secure funding on acceptable terms [sec_mda · as of 2026-08-10].
- History of net losses and no revenue — The company has an accumulated deficit of $648.3 million and expects ongoing losses with no product revenue [sec_mda · as of 2026-03-25].
- Uncertainty in clinical development — Clinical trials are costly and unpredictable, with timing and outcomes subject to many factors [sec_mda · as of 2026-08-10].
What to watch
- Progress and results of ongoing clinical trials for NK cell therapy candidates [sec_mda · as of 2026-08-10].
- Ability to raise additional capital through equity, debt, or partnerships [sec_mda · as of 2026-08-10].
- Updates on manufacturing process development and regulatory interactions [sec_mda · as of 2026-08-10].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Nkarta, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Nkarta, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
22.1 months
D/E 0.36 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
121
Total value held
$96.5M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 10,805,129 | $22.8M |
| blackrock, inc. | 4,508,473 | $9.5M |
| vanguard capital management llc | 4,022,842 | $8.5M |
| samsara biocapital, llc | 3,507,666 | $7.4M |
| alyeska investment group, l.p. | 2,084,840 | $4.4M |
| two sigma investments, lp | 2,047,376 | $4.3M |
| citadel advisors llc | 1,805,094 | $3.8M |
| renaissance technologies llc | 1,732,372 | $3.7M |
| wasatch advisors lp | 1,577,847 | $3.3M |
| tang capital management llc | 1,480,823 | $3.1M |
Showing top 10 of 121 institutional holders of Nkarta, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 9.3%
- Days to cover
- 5.6
- Shares short
- 5,272,916
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NKTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Nkarta, Inc.?
Nkarta, Inc. is a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies for cancer, with a focus on advancing its pipeline through clinical trials while managing significant capital requirements and operating losses.
What is Nkarta, Inc.'s lead drug candidate?
Nkarta, Inc.'s most advanced tracked candidate is nkx019 (Phase 1) for Lupus Nephritis; Systemic Sclerosis; Lymphoma, Non-Hodgkin.
Who is the CEO of Nkarta, Inc.?
Mr. Paul J. Hastings is the chief executive officer of Nkarta, Inc. (NKTX).
Where is Nkarta, Inc. headquartered?
Nkarta, Inc. (NKTX) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Nkarta, Inc. focus on?
Nkarta, Inc. develops therapies across Oncology, Gene Therapy, Immunology, Nephrology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.